HYPOGLYCEMIC EFFECT OF LUPIN ALKALOIDS AND/OR ROSIGLITAZONE IN PREGNANT DIABETIC RATS IN RELATION TO ATHEROGENIC INDEX
Keywords:
Atherogenic index (AIP), Homeostasis model assessment of insulin resistance (HOMA-IR), Type two diabetes, Lupin alkaloids, RosiglitazoneAbstract
Diabetes (DM) is a group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion and/ or insulin action. It can be classified into; type 1 (T1DM) Type 2 DM, type 2 (T2DM), gestational diabetes and other specific types of diabetes. Diabetes is the most common pre-existing medical condition complicating pregnancy. Insulin resistance is associated with both type two diabetes and dislypedemia. This study aims to evaluate the changes in the homeostasis model assessment of insulin resistance (HOMA- IR) and indices of atherogenic lipid profile parameters in pregnant diabetic rats after the administration of Rosiglitazone and /or alkaloid lupine extract. Blood glucose, hemoglobin content (Hb), lipid profile, insulin and glucagon concentrations were investigated at 20th day of gestation. The results revealed the improvement of HOMA-IR and The control of the hyperglycemic status in all treated group. Also, there are an increase in insulin concentration, and a decrease in glucagon concentration in all treated groups, in comparison to, STZ group. Meanwhile, it showed alternation in the atherogenic profile in Rosiglitazone treated groups, in comparison to, lupin treated groups. The correlations among (HOMA-IR and HDL), (AIP and LDL) and (glucose and Hb) were observed in our study at (r = 0.594, p< 0.01), (r = 0.690, p< 0.01), and (r = 0.811, p< 0.01) respectively. The usage of lupine alkaloids to treating type two diabetes during the pregnancy is more favorable to avoid Rosiglitazone side effects. More studies are needed to explore the effect of Rosiglitazone on lipids and cardiovascular risk.
Downloads
References
American Diabetes A. "Diagnosis and classification of diabetes mellitus." Diabetes Care 2013;(36 Suppl 1):74.
Shaw J, R Sicree, P Zimmet. "Global estimates of the prevalence of diabetes for 2010 and 2030." Diabetes Res Clin Pract 2010;87(1):4-14.
Navneet M. "Gestational diabetes mellitus: Get, set, go From diabetes capital of the world to diabetes care capital of the world." Indian J Endocrinol Metab 2011;15(3):161-9.
Inkster M, Fahey T, Donnan P, Leese G, Mires G, Murphy D. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy Childbirth 2006;6:30.
Jawerbaum A, V White. "Animal models in diabetes and pregnancy." Endocrine Rev 2010;31(5):680-701.
Feig D, Palda V. Type 2 diabetes in pregnancy: a growing concern. Lancet 2002;359:1690-2.
Aasa K, Kwong K, Adams M, Croy B. Analysis of maternal and fetal cardiovascular systems during hyperglycemic pregnancy in the nonobese diabetic mouse. Biol Reprod 2013;88:151.
Hawthorne G. Maternal complications in diabetic pregnancy. Best Practice Res Clin Obstet Gynaecol 2011;25:77–90.
Hare J. "Birth defects in infants of diabetic mothers: a historical review." Insulin; 2009.
Barbour L, McCurdy C, Hernandez T, Kirwan J, Catalano P, Friedman J. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007;30:S112–S9.
Osman M, F Sarkar. "A molecular rheostat at the interface of cancer and diabetes." Biochim Biophys Acta 2013;1836(1):166-76.
Ashcroft F, P Rorsman. "Diabetes mellitus and the β cell: the last ten years." Cell 2012;148(6):1160-71.
Graham E, F Adler. "Long-term models of oxidative stress and mitochondrial damage in insulin resistance progression." J Theor Biol 2014;340:238-50.
Zhu X-W, Deng F-Y, Lei S-F. Meta-analysis of atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus. Primary Care Diabetes 2014; 35(5):696-8.
Onyedum C, Young E, Iroezindu M, Chukwuka C, Nwagha U. Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria. Indian J Endocrinol Metab 2014;18:631–6.
Keska A, Lutoslawska G, Czajkowska A, Tkaczyk J, Mazurek K. Variability in HOMA-IR, Lipoprotein Profile and Selected Hormones in Young Active Men. The Sci World J 2013;14;2013:4127-64.
Okita K, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J 2013;60:283–90.
Catalano P. Obesity, insulin resistance, and pregnancy outcome. Reprod (Cambridge, England) 2010;140:365–71.
Pagliuca F, D Melton. "How to make a functional β-cell." Dev (Cambridge, England) 2013;140(12):2472-83.
Hemmeryckx B, Gaekens M, Gallacher D, Lu H, Lijnen H. Effect of Rosiglitazone on liver structure and function in genetically diabetic Akita mice. Basic Clin Pharmacol Toxicol 2013;113:353–60.
Raman KV, K Vijay. "3D-QSAR study of tyrosine and propanoic acid derivatives as PPARα/γ dual agonists using CoMSIA." Med Chem Res 2012;22(1):287-302.
Zhou L, Liu G, Jia Z, Yang K, Sun Y, Kakizoe Y. Increased susceptibility of db/db mice to Rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters. Am J Physiol Regul Physiol 2013;305:F1491–F7.
Loke Y, C Kwok. "Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies." BMJ Clin Res 2011;17:342-d1309.
US Food. Drug Administration (November 25, 2013). "FDA requires removal of certain restrictions on the diabetes drug Avandia†http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm.
Hui H, G Tang, V Go. "Hypoglycemic herbs and their action mechanisms." Chin Med 2009;4:11.
Fornasini M, J Castro, E Villacrés, L Narváez, M Villamar, M Baldeón. "Hypoglycemic effect of Lupinus mutabilis in healthy volunteers and subjects with dysglycemia." Nutr Hosp 2012;27(2):425-33.
Annicchiarico P, P Manunza, A Arnoldi, G Boschin. "Quality of Lupinus albus L. (white lupin) seed: extent of genotypic and environmental effects." J Agric Food Chem 2014;62(28):6539-45.
Osman M, Mahmoud G, Romeilah R, Fayed S. Lupin seeds lower plasma lipid concentrations and normalize antioxidant parameters in rats. Grasas y Aceites 2011;62:162-70.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res/ Academia Scientiarum Bohemoslovaca 2001;50:537–46.
Atamer Y, Atamer A, Can AS, Hekimoglu A, Ilhan N, Yenice N, et al. Effects of Rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus. Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de BiofÃsica 2013;46:528–32.
Karara H. An efficient method for the extraction of alkaloids from bitter lupin seed. Fett Wissenschaft Technol/Fat Sci Technol 1987;89:442–6.
Robbins MC. "A 90-day feeding study of the alkaloids of Lupinus angustifolius in the rat." Food Chem Toxicol 1996;34(8):679-86.
Murthy H, Dandin V, Lee E, Paek K. Efficacy of ginseng adventitious root extract on hyperglycemia in streptozotocin-induced diabetic rats. J Ethnopharmacol 2014;153:917-21.
Naz R, Chauhan S. Human sperm-specific peptide vaccine that causes long-term reversible contraception. Biol Reprod 2002;67:674–80.
Robertson S, Guerin L, Bromfield J, Branson K, Ahlström A, Care A. Seminal fluid drives expansion of the cd4+cd25+ t regulatory cell pool and induces tolerance to paternal alloantigens in mice. Biol Reprod 2009;80:1036–45.
Van Kampen E, Zijlstra W, Assendelft V, Reinkingh W. Determination of hemoglobin and its derivatives. Adv Clin Chem 1965;8:141-87.
Kaplan A, Glucose, Kaplan A. Clin Chem The CV Mosby Co. St Louis. Toronto. Princeton; 1984. p. 1032-6.
Ellefson RE, Caraway WT. Lipids and lipoproteins, "in fundamentals of clinical chemistry. Edited by Norbert and Tietz Philadelphia, Saunders; 1976. p. 506.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge 1972;18(6):499-502.
Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476–82.
Damanhouri LH. Angiogenic factors in children and adolescents with type 1 diabetes mellitus. J Am Sci 2013;9(7):269-77.
Okita K, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J 2013;60:283–90.
Shim W, Do M, Kim S, Kim H, Hur K, Kang E. The long-term effects of Rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol 2006;65:453-9.
Dobiásová M, Frohlich J, Sedová M, Cheung M, Brown B. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res 2011;52:566–71.
Hod M, Yogev Y. Goals of metabolic management of gestational diabetes: is it all about the sugar? Diabetes Care 2007;30 Suppl 2:S180–S7.
Kim J-S, Kang H-T, Shim J-Y, Lee H-R. The association between the triglyceride to high-density lipoprotein cholesterol ratio with insulin resistance (HOMA-IR) in the general Korean population: based on the national health and nutrition examination survey in 2007–2009. Diabetes Res Clin Pract 2012;97:132-8.
Eliza J, Daisy P, Ignacimuthu S, Duraipandiyan V. Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.)Sm in STZ-induced diabetic rats. Chem Biol Int 2009;182:67–72.
Elbatran S, Abdelsalam O, Nofal S, Baiuomy A. Effect of Rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats. Pharmacol Res 2006;53:69-74.
Pandit R, Phadke A, Jagtap A. Antidiabetic effect of Ficus religiosa extract in streptozotocin-induced diabetic rats. J Ethnopharmacol 2010;128:462–6.
Gurney A, Howarth F. Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries. Cardiovasc Diabetol 2009;8:4.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res/ Academia Scientiarum Bohemoslovaca 2001;50:537–46.
Mohammady I, Elattar S, Mohammed S, Ewais M. An evaluation of anti-diabetic and anti-lipidemic properties of Momordica charantia (Bitter Melon) fruit extract in experimentally induced diabetes. Life Sci J 2012;9:363–74.
Liu L, Aronson J, Lecka-Czernik B. Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration. Bone 2013;52:247–58.
Malecki, M. "Genetics of type 2 diabetes mellitus." Diabetes Res Clin Pract 2005;68 Suppl 1:21.
Mohamed W, Sherbiny G, Zaki H, Sayed M. Possible modulation of the antidiabetic effect of Rosiglitazone by buspirone. Bull Fac Pharm Cairo University 2012;50:73-9.
Hsiao G, Chapman J, Ofrecio J, Wilkes J, Resnik J, Thapar D, et al. Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats. Am J Physiol Endocrinol Metab 2011;300:E164–E74.
Zhao Z, Lee Y-J, Kim S-K, Kim H-J, Shim W-S, Ahn C-W, et al. Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. Life Sci 2009;84:688–95.
Derosa G, Salvadeo S, D’Angelo A, Fogari E, Ragonesi P, Ciccarelli L, et al. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Arch Med Res 2008;39:412–9.
Samaha F, Szapary P, Iqbal N, Williams M, Bloedon L, Kochar A, et al. Effects of Rosiglitazone on Lipids, Adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;26:624–30.
Kim Y, Cha B, Kim D, Choi S, Kim S, Ahn C, et al. Predictive clinical parameters for therapeutic efficacy of Rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;67:43-52.
Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005;70:20-5.
McGuire D, S Inzucchi. "New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications." Circulation 2008;117(3):440-9.
Farrag A, Khalil M, Hussein J. Hypoglycemic effect of selected herbal extracts on streptozotocin induced diabetic ratsâ€. J Appl Sci Res 2008;4(12):2001-12.
Fornasini M, Castro J, Villacrés E, Narváez L, Villamar M, Baldeón M. Hypoglycemic effect of Lupinus mutabilis in healthy volunteers and subjects with dysglycemia. Nutr Hosp 2012;27:425–33.
Bobkiewicz-Kozłowska T, Dworacka M, Kuczyński S, Abramczyk M, Kolanoś R, Wysocka W, et al. Hypoglycaemic effect of quinolizidine alkaloids — lupanine and 2-thionosparteine on non-diabetic and streptozotocin-induced diabetic rats. Eur J Pharmacol 2007;565:240-4.
Reinhard H, Rupp H, Sager F, Streule M, Zoller O. Quinolizidine alkaloids and phomopsins in lupin seeds and lupin containing food. J Chromatogr A 2006;1112:353-60.
López P, Mora P, Wysocka W, Maiztegui B, Alzugaray M, Zotto H, et al. Quinolizidine alkaloids isolated from Lupinus species enhance insulin secretion. Eur J Pharmacol 2004;504:139-42.
Brekke I, Danielsen H, Reith A. Normalization of hepatic lysosomal autophagy in streptozotocin diabetic rats after pancreatic transplantation. Virchows Arch B Cell Pathol Incl Mol Pathol 1983;43:189–97.
Atanasovska E, Tasic V, Slaninka-Miceska M, Alabakovska S, Zafirov D, Kostova E, et al. Six week follow-up of metabolic effects induced by a high-fat diet and streptozotocin in a rodent model of type 2 diabetes mellitus. Contributions Sec Med Sci 2014;35(1):169-79.
Yildirim S, Bolkent S, Sundler F. The role of Rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study. J Mol Histol 2008;39:635–42.
Bloomgarden Z. Role of glucagon in treating diabetes: evidence and concepts. J Diabetes 2014;6:93-5.
Schinner S, Dellas C, Schröder M, Heinlein C, Chang C, Fischer J, et al. Repression of glucagon gene transcription by peroxisome proliferator-activated receptor γ through inhibition of pax6 transcriptional activity. J Biol Chem 2002;277:1941–8.
Sgambato S, Paolisso G, Passariello N, Varricchio M, D’Onofrio F. Effect of sparteine sulphate upon basal and nutrient-induced insulin and glucagon secretion in normal man. Eur J Clin Pharmaco 1987;32:477–80.
Mansour S, Zaki H, EleDenshary Ezz. Chromium picolinate and Rosiglitazone improve biochemical derangement in a rat model of insulin resistance: role of tnf-α and leptin. Pharmacol 2013;4(3):186-96.
Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo R. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72:1367–73.
Samaha F, Szapary P, Iqbal N, Williams M, Bloedon L, Kochar A, et al. Effects of Rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;26:624–30.
Calkin A, Forbes J, Smith C, Lassila M, Cooper M, Jandeleit-Dahm K, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005;25:1903–9.
Home P, Pocock S, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (record): study design and protocol. Diabetol 2005;48:1726–35.
Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53–8.
Li S, Basnakian A, Bhatt R, Megyesi J, Gokden N, Shah S, et al. PPAR-ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. AJP Renal Physiol 2004;287:F990–F8.
Deeg M, Tan M. Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Research; 2008.
Sidhu J, Cowan D, Kaski J-C. The effects of Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757-63.
Farghaly A, Z Hassan. "Methanolic extract of Lupinus termis ameliorates DNA damage in alloxan-induced diabetic mice." Eur Rev Med Pharmacol Sci 2012;16 Suppl 3:126-32.
Hall R, Johnson S, Baxter A, Ball M. Lupin kernel fibre-enriched foods beneficially modify serum lipids in men. Eur J Clin Nutr 2004;59:325–33.
Newairy A-S, Mansour H, Yousef M, Sheweita S. Alterations of lipid profile in plasma and liver of diabetic rats: effect of hypoglycemic herbs. J Environ Sci Health Part 2002;B 37:475–84.
Martins JM, Riottot M, Abreu MC de, Viegas-Crespo AM, Lança MJ, Almeida JA, et al. Cholesterol-lowering effects of dietary blue lupin (Lupinus angustifolius L.) in intact and ileorectal anastomosed pigs. J Lipid Res 2005;46:1539–47.
Bettzieche A, Brandsch C, Eder K, Stangl G. Lupin protein acts hypocholesterolemic and increases milk fat content in lactating rats by influencing the expression of genes involved in cholesterol homeostasis and triglyceride synthesis. Mol Nutr Food Res 2009;53:1134–42.
Besbes M, TalebSenouci D, Chabane F, Daij N, Lamri Senhadji M. Effects of white lupin associated with wheat or oat on hyperglycemia, dyslipidemia and reverse cholesterol transport in obese rats. J Exper Int Med 2013;3(3):205-12.
Spielmann J, Shukla A, Brandsch C, Hirche F, Stangl GI, Eder K. Dietary lupin protein lowers triglyceride concentrations in liver and plasma in rats by reducing hepatic gene expression of sterol regulatory element-binding protein-1c. Ann Nutr Metab 2007;51:387–92.
Muruganandan S, Srinivasan K, Gupta S, Gupta P, Lal J. Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J Ethnopharmacol 2005;97:497-501.
Moon J, Kim H, Kim H, Yang A, Lee B-W, Kang E, et al. Upregulation of hepatic LRP1 by Rosiglitazone: a possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia. J Mol Endocrinol 2012;49:165–74.
Calkin A, Forbes J, Smith C, Lassila M, Cooper M, Jandeleit-Dahm K, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005;25:1903–9.
Sidhu J, Cowan D, Kaski J-C. The effects of Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am College Cardiol 2003;42:1757-63.
Nivitabishekam S, Asad M, Prasad V. Pharmacodynamic interaction of Momordica charantia with Rosiglitazone in rats. Chem Biol Interact 2009;177:247–53.
Arora M, Reddy K, Balakumar P. The low dose combination of fenofibrate and Rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol 2010;636:137–44.
Abbasi F, Okeke Q, Reaven G. Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR). Acta Diabetologica 2013;51:193-7.
Rye K-A, Bursill C, Lambert G, Tabet F, Barter P. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009;50 Suppl: S195–200.
Rohlfing CL, Wiedmeyer H-MM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 2002;25:275–8.
Annicchiarico P."Quality of Lupinus albus L. (white lupin) seed: extent of genotypic and environmental effects." J Agric Food Chem 2014;62(28):6539-45.
Pari L, R Saravanan. "Antidiabetic effect of diasulin, a herbal drug, on blood glucose, plasma insulin and hepatic enzymes of glucose metabolism in hyperglycaemic rats." Diabetes Obes Metab 2004;6(4):286-92.